Hitco's History

Mr. Jamshid Babaie began his commercial career in 1965 (1344) at Tolid Darou Company under the management of Mr. Khosrowshahi. His years working alongside Mr. Khosroshahi were filled with invaluable experiences and the development of personal and entrepreneurial skills under the mentorship of that distinguished businessman. After four years at Tolid Darou, Mr. Babaie , in pursuit of his personal aspirations, accepted an offer to join Don Baxter Company—now known as Iran Injectables Products Company. At the time, Don Baxter was primarily focused on the production and sale of intravenous solutions. Later, through his involvement with IRAN HOECHST, Mr. Babaie entered the field of specialized pharmaceuticals. Following the establishment of his own pharmaceutical manufacturing plant, he transitioned to working directly with Iran Hoechst and ultimately secured exclusive representation of the company in FARS Province—a step that marked a major milestone in his business career at the time.

Between 1970 and 1980 (1349 to 1359), significant transformations took place within the operations of HOECHST Germany in Iran, much of which was the result of Mr. Babaei’s tireless efforts and dedication. Unfortunately, in 1980 (1359), with the onset of the Iran-Iraq war, all multinational companies—including Hoechst Germany—decided to withdraw from Iran.

In 1981 (1360), Mr. Babaei resumed his business activities through two companies—Aradco and Shiraz Behdasht—as the exclusive representative of LATON Germany, focusing on the supply of surgical items and various single-use medical products. Eventually, in 1998 (1377), due to changes in import regulations and a growing emphasis on domestic production of certain medical items, he transitioned into manufacturing through Varian Teb Company, the exclusive distributor of surgical sutures. In addition to sutures, other disposable products that could be packaged locally were also added to the company’s product portfolio.

In 2002 (1381), Mr. Babaei ultimately joined the Teb Novin group, while simultaneously continuing his commercial activities until 2005 (1384). During this time, he played a significant role in the development and expansion of Teb Novin’s product portfolio.

In 2005 (1384), following the completion of his studies, Mr. Ali Babaei joined the Teb Novin group. Eventually, Mr. Jamshid Babaei entrusted all his responsibilities to him. Mr. Ali Babaei’s entry into the business, leveraging the strategic foundation laid by Mr. Jamshid Babaei in the field of medical disposable sales, led to a significant transformation in the company’s performance—culminating in Mr. Babaei achieving the highest sales figures across the entire organization. His focused approach and commitment to business development in a competitive environment led to an independent invitation to become a shareholder in the company. He subsequently gained hands-on experience across all major departments, including marketing, business development, and finance, as part of a long-term trajectory to prepare him for future company leadership. Mr. Babaei has undertaken numerous business initiatives, many of which have become points of pride for the organization. Among his notable achievements is securing multiple exclusive distribution agreements with globally recognized brands such as 3M, Teleflex, and Hartmann in the field of single-use medical devices.

In 2010 (1389), Mr. Ali Babaei made the decision to part ways with Iran Pharmis and Momtaz National Distribution Company. He then went on to establish an independent company named Tamin Darou, through which he successfully obtained the exclusive representation of the renowned company John O. Butler, for the distribution of its brands GUM and Butler. Tamin Darou was positioned as the pilot company for cosmetics and personal care products within the group. Today, the Hitco Group of Companies is actively serving in a wide range of industries, including pharmaceuticals, nutritional supplements, food products, and medical equipment.

Rasta Imen Darou was established in 2012 (1391) with the goal of providing high-quality pharmaceutical products and specialized supplements to the Iranian healthcare market.

Pak Salamat Tamin was established with the aim of importing and producing various nutritional, pharmaceutical, sports supplements, and prescription probiotics.

Tamin Pharmed Tehran was established with the aim of licensed production, importing emergency medicines, and manufacturing various types of herbal medicines.

Tamin Shafa Pars was established with the aim of importing and producing single-use medical supplies, as well as importing highly specialized products—particularly for dialysis and diabetic patients..

Kiara Zist Pharmed was established as a knowledge-based company with the aim of producing high-quality skin and hair care products based on bioactive ingredients.

It was established with the aim of producing various pharmaceutical-grade aesthetic products such as different types of fillers, mesotherapy solutions, lifting threads, as well as the production of botulinum toxin (Botox), and offering a full range of beauty products in a pharmaceutical format..

It was established with the aim of licensed production of biotechnology-based medicines from leading international companies, as well as the licensed production of neurological supplements.

Salamat Investment Holding acquired shares and manufacturing facilities of Zhoobin Mehr Food Industries with the aim of producing health-oriented, dietary, and organic food products under the brand name CANFOOD.

In 2023 (1402), Salamat Investment Holding acquired a stake in the knowledge-based company Novin Darou Zist Fanavar Haraz, with the aim of producing plasma-derived medicinal products for the treatment of patients.

In 2023 (1402), by acquiring a stake in the knowledge-based company Kara Yakhteh Tajhiz Azma, Salamat Investment Holding expanded its activities in the field of cancer treatment in Iran and the region. This initiative involved forming a specialized research team focused on the “development and characterization of engineered lymphocytes equipped with nanobody-based chimeric antigen receptors (CARs) for use in immunocellular therapy of cancer,” as well as the production of a childhood leukemia vaccine.

It began operations in the field of veterinary medicine through licensed production and local manufacturing.

It was established with the aim of producing recombinant knowledge-based drugs domestically, including interferons (alpha, beta, gamma), human growth hormone, and parathyroid hormone..

It was established for the production and import of various human vaccines, with the aim of developing local expertise as well as bulk manufacturing and domestic packaging.

It was established with the aim of licensed production of biotechnology-based medicines, including various mAbs (monoclonal antibodies) and other biotech products, as well as the import of selected biotechnology items.